Knowledge

Agentic AI will autonomously manage vendor vetting, real-time risk monitoring, and coordinated response playbooks—reducing procurement cycle times and preventing supply disruptions while operating under human-defined guardrails. HHG GROUP’s platform experience shows these agents cut downtime and speed secure trades by automating multi-step workflows. Bio Medical Procurement Strategy: Balancing Innovation with Budgetary Constraints What is Agentic […]

The FDA’s 510(k) clearance of the Cala kIQ Plus in April 2026 marks a significant advancement in non-invasive tremor management. This next-generation wearable features adaptive calibration and new therapy modes, offering a more personalized and effective treatment for patients with Essential Tremor (ET) and Parkinson’s Disease (PD) tremor. It represents a leap forward in accessible,

Trinity Capital’s $50 million growth capital investment in Cala Health represents a pivotal vote of confidence in the future of non-invasive neuromodulation. This infusion will accelerate the commercial scale-up of Cala’s TAPS therapy, a wearable device designed to treat essential tremor, expanding patient access and driving next-generation innovation in a high-growth medical device segment. Medical

Presented at the American Academy of Neurology 2026 Annual Meeting, data from Cala’s Poster P5-005 demonstrated that the kIQ system’s novel variable waveforms achieved significantly higher responder rates in treating essential tremor. This advancement represents a meaningful step in personalized neuromodulation, offering a more adaptable and potentially more effective therapy by dynamically adjusting stimulation patterns

The NeurologyLive TAPSA 2026 report underscores a pivotal shift in bioelectronic medicine, moving decisively from generic stimulation to personalized neuromodulation. This evolution, exemplified by devices like the kIQ Plus, tailors therapy to an individual’s unique neurophysiological signature for superior outcomes in conditions like tremor. It represents a fundamental rethinking of how medical devices interact with

Neurology groups wanting to add TAPS‑based neuromodulation often run into the same problem: the device feels like a high‑risk capital purchase because Medicare reimbursement rules look contradictory, coding is murky, and billing staff are unsure whether the Cala kIQ and similar TAPS stimulators qualify as durable medical equipment (DME) under Part B or get pushed

In January 2026, UBC Okanagan researchers advanced a “passive” tremor-reducing brace, a non-electronic device using mechanical principles to absorb and dissipate kinetic energy from hand tremors. This innovation offers a battery-free, maintenance-light alternative to active neurostimulation devices, potentially improving accessibility and daily usability for patients with essential tremor or Parkinson’s disease. Medical Equipment Store |

The global essential tremor treatment market, valued at $210 million in March 2026, is a dynamic sector driven by the increasing adoption of non-invasive wearable technology and a growing demand for effective, patient-centric solutions. This growth, projected at a 5.1% CAGR, reflects a shift from traditional pharmaceuticals to advanced neuromodulation devices, creating a complex landscape

Supply Chain Resilience: Cala’s “Direct-to-Clinic” Model represents a strategic pivot in medical device distribution, focusing on bypassing traditional multi-tiered channels to deliver essential tremor therapy devices like the kIQ directly to healthcare providers. This model, highlighted in a 2026 logistics report, is a proactive response to global supply chain volatility, ensuring consistent patient access through

In mid-2026, Cala Therapeutics announced its pursuit of the CE Mark and Japanese PMDA approval for its kIQ Plus wearable therapy for essential tremor. This strategic global expansion into the EU and Asian markets represents a significant shift, aiming to bring the non-invasive neuromodulation device to millions of new patients. For medical equipment traders and